Capecitabine + Pembrolizumab
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Estrogen Receptor Negative
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Trial Timeline
May 25, 2017 → May 1, 2021
NCT ID
NCT03044730About Capecitabine + Pembrolizumab
Capecitabine + Pembrolizumab is a phase 2 stage product being developed by Merck for Estrogen Receptor Negative. The current trial status is unknown. This product is registered under clinical trial identifier NCT03044730. Target conditions include Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03044730 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Estrogen Receptor Negative